medigraphic.com
ISSN 1684-1824 (Electronic)

2019, Number 4

<< Back Next >>

Rev Méd Electrón 2019; 41 (4)

Polycystic ovary syndrome, an entity demanding an early diagnosis

Balceiro BL, Inda PD, Garay CMI, Álvarez EMC, Domínguez SN, Quiñones BA

Language: Portugués
References: 33
Page: 940-958
PDF size: 797.84 Kb.


ABSTRACT

Polycystic ovary syndrome has become a public health problem, being the most common of the endocrine disorders in reproductive-age women, with studies reporting prevalence by 21 %. The diagnosis of this entity is important because it represents metabolic and cardiovascular risk, and affects the reproductive capacity of these patients. The authors carried out bibliographic review of the main articles related with the theme, summarizing the basic aspects of this health problem.


REFERENCES

  1. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014;20(26):8351-63. Citado en PubMed: PMID: 25024594.

  2. Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arq Bras Endocrinol Metabol. 2014;58(2):182-7. Citado en PubMed: PMID:24830595.

  3. Cirik DA, Dilbaz B. What do we know about metabolic syndrome in adolescents with PCOS? J Turk Ger Gynecol Assoc. 2014;15(1):49-55. Citado en PubMed: PMID:24790517.

  4. Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014;6:104-19. Citado en PubMed: PMID:24389146.

  5. Vázquez-Bañuelos A, Delgado-Martínez A, Fuentes-Gómez C, et al. Síndrome de Ovario Poliquístico. Rev Medicina Clín [Internet].2018 [citado 03/03/2018];(2):2. Disponible en: https://medicinaclinica.org/index.php?journal=rmc

  6. McCartney CR, Marshall JC. Polycystic Ovary Syndrome. N Engl J Med. 2016;375(1):54-64. Citado en PubMed: PMID: 27406348.

  7. Rosenfield RL. Hirsutism. N Engl J Med. 2005;353(24):2578-88. Citado en PubMed: PMID: 16354894.

  8. Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487-525. Citado en PubMed: PMID: 26426951.

  9. Diamanti-Kandarakis E, Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr Rev. 2012;33(6):981-1030. Citado en PubMed: PMID: 23065822.

  10. Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical endocrinologistis, American college of endocrinology, and androgen excess and pcos society disease state clinical review:guide to the best practices in the evaluation and treatment of polycystic. Endocr Pract. 2015;21(12):1415-426. Citado en PubMed: PMID: 26642102.

  11. Falsetti L, Gambera A, Andrico S, et al. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16(4):275-84. Citado en: PubMed: PMID:12396556.

  12. Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S, et al. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome. J Health Popul Nutr. 2015;33(1):157-67.Citado en PubMed: PMID: 25995732.

  13. Dagogo-Jack S, Al-Ali N, Qurttom M. Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab. 1997;82(9):2821-5. Citado en PubMed: PMID: 9284703.

  14. Hyderali B, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2015;191:15-22. Citado en PubMed: PMID: 26066290.

  15. Glintborg D, Sidelmann JJ, Altinok ML, et al. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. Metabolism. 2015;64(10):1272-8. Citado en PubMed: PMID: 26194691.

  16. Bui HN, Sluss PM, Hayes FJ, et al. Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. Clin Chim Acta. 2015;450:227-32. Citado en PubMed: PMID: 26327459.

  17. O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab. 2014;99(3):1027-36. Citado en PubMed: PMID: 24423344.

  18. Janse F, Eijkemans MJ, Goverde AJ, et al. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. Eur J Endocrinol. 2011;165(6):925-33. Citado en PubMed: PMID: 21969522.

  19. Pizzi R, Centeno I, Fung L, et al. Niveles de hormona antimülleriana en pacientes con síndrome de ovario poliquístico. Rev Obstet Ginecol Venez. 2015;75:250-59.

  20. Checa Vizcaíno MA, Espinós Gómez J, Matorras Weining R. Síndrome del ovario poliquístico. España: Editorial Médica Panamericaba; 2006.

  21. The Rotterdan ESHRE/ASRM-sponsored PCOS consensus Workshop Group. Revised 2003 Consensus on diagnostic criteria for polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. Citado en PubMed: PMID: 14711538.

  22. Spritzer P. Polycystic Ovary Syndrome: reviewing diagnosis and management of metabolic disturbances: Arq Bras Endocrinol Metab. 2014;58(2):182-87. Citado en PubMed: PMID: 24830595.

  23. Dewaily D, Lujan M, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from Androgen Excess and Polycystic Ovaria Syndrome Society. Human Reproducction Update 2014;20(3):334-52. Citado en PubMed: PMID: 24345633.

  24. Witchel SF, Oberfield S, Rosenfield RL, et al. The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr 2015;83:376-89. Citado en PubMed: PMID: 25833060.

  25. Wang R, Kim B V, Van Wely M, et al.Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017:j138. Citado en PubMed: PMID: 28143834.

  26. Hamilton-Fairley D, Taylor A. Anovulation. BMJ. 2003;327(7414):546-49. Citado en PubMed: PMID:12958117.

  27. Kobelt G, Phillips G, Jenny Berg JE. The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms. Mult Scler J. 2017;23(2s):153-56. Citado en PubMed: PMID: 28643592.

  28. Amiri M, Kabir A, Nahidi F, et al. Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Heal Care. 2018;23(1):64-77. Citado en PubMed: PMID: 29457756.

  29. Pergialiotis V, Trakakis E, Chrelias C, et al. The impact of mild hypercholesterolemia on glycemic and hormonal profiles, menstrual characteristics and the ovarian morphology of women with polycystic ovarian syndrome. Horm Mol Biol Clin Investig. 2018;34(3):1-6. Citado en PubMed: PMID: 29596052.

  30. Skubleny D, Switzer NJ, Gill RS, et al. The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis. Obes Surg. 2016;26(1):169-76. Citado en PubMed: PMID: 26431698.

  31. Thomson RL, Buckley JD, Brinkworth GD. Perceived exercise barriers are reduced and benefits are improved with lifestyle modification in overweight and obese women with polycystic ovary syndrome: A randomised controlled trial. BMC Womens Health. 2016;16(1). Citado en PubMed: PMID: 26960762.

  32. Wang J, Zhu L, Hu K, et al. Effects of metformin treatment on serum levels of Creactive protein and interleukin-6 in women with polycystic ovary syndrome: a metaanalysis: A PRISMA-compliant article. Medicine (Baltimore). 2017;96(39):e8183. Citado en PubMed: PMID: 28953677.

  33. Barber TM, Dimitriadis GK, Andreou A, et al. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. Clin Med (Northfield Il). 2015;15(Suppl_6):s72-s76.Citado en PubMed: PMID: 26634686.




2020     |     www.medigraphic.com